Costco set to open 4 new US locations in August. Here's where.
The next wave of stores comes on the heels of three new openings in South Korea, Sweden, and Midland, Texas in June and July, as well as a handful of new stores that opened in the U.S. this spring.
The wholesale warehouse juggernaut is a staple of American shopping and a cult hero for shoppers around the world, with millions of card-carrying members and hundreds of locations in the U.S. and abroad.
Costco aims to open 25-30 new locations each year, typically with half of them in the U.S. and the other half in international markets, chief financial officer Gary Millerchip said in March.
Here is where Costco is opening next month.
How Costco hooks shoppers: Come for the hot dogs, stay for the gold bars
Where is Costco opening stores?
Costco lists seven locations with future opening dates in August on its "Coming Soon" page.
USA TODAY has reached out to Costco for more information.
Where has Costco opened stores recently?
Costco opened stores in March, April, June and July this year:
USA TODAY's James Powel and Mike Snider contributed to this report.
Fernando Cervantes Jr. is a trending news reporter for USA TODAY. Reach him at fernando.cervantes@gannett.com and follow him on X @fern_cerv_.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
CRSP, ABSI, IRDM: Cathie Wood Offloads $16.4M of CRISPR Therapeutics Stock, Buys Absci and Iridium
Ace hedge fund manager Cathie Wood made some interesting trades on July 25, according to ARK Invest's daily trade updates. Wood sold $16.46 million worth of biotechnology company Crispr Therapeutics (CRSP) and $2.15 million of defense contractor Kratos Defense (KTOS) stock. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Meanwhile, ARK funds added $6.2 million in biotechnology firm Absci Corp. (ABSI), purchased 262,141 shares of genomic diagnostics company Veracyte (VCYT), and acquired 69,969 shares of satellite company Iridium Communications (IRDM). Wood Buys the Dip in Absci Stock On July 25, Wood loaded up on 2.25 million shares of Absci, totaling $6.2 million. Absci leverages generative artificial intelligence (AI) and synthetic biology to develop novel biologic drugs, primarily antibodies, for pharmaceutical and biotechnology partners. ABSI stock plunged 17.7% on Friday after the company announced a $50 million secondary offering of its common shares. Wood seems to have capitalized on the 'dip' in Absci shares to gain a notable position. All seven analysts tracking ABSI stock have rated it a Strong Buy on TipRanks. The average Absci price target of $9.17 implies an impressive 217.3% upside potential from current levels. Year-to-date, ABSI stock has gained 10.3%. Why Is Wood Dumping CRSP Stock? Wood appears to have taken a bearish stance on gene-editing company Crispr, although she maintains a rather optimistic outlook on the overall genomics sector. On Friday, The ARK Innovation ETF (ARKK) sold 190,840 shares of Crispr worth $12.6 million, and the ARK Genomic Revolution ETF (ARKG) sold another 58,268 shares of CRSP for $3.8 million. Crispr is a Swiss-American biotech company focused on developing transformative gene-based medicines to treat serious diseases such as sickle cell disease, beta-thalassemia, various cancers, type 1 diabetes, and cardiovascular diseases. It uses advanced gene-editing technology, primarily its CRISPR/Cas9 platform, to develop its medicines. Despite the latest sale, CRSP remains the largest holding in the ARKG fund, with a market value of $137.5 million, and is also the fourth largest holding in the ARKK fund, with a market value of $450.6 million. Notably, CRSP stock has surged over 64% so far this year, backed by its revolutionary business model. Crispr is expected to release its Q2FY25 results in August. Wall Street expects CRSP to report a diluted loss of $1.4 per share, 1.3% better than the prior year's loss of $1.49. Revenues are expected to jump nearly 1100% year-over-year to $6.14 million. On TipRanks, CRSP stock has a Moderate Buy consensus rating based on 14 Buys and seven Hold ratings. Also, the average Crispr Therapeutics price target of $69.38 implies 7.1% upside potential from current levels. Year-to-date, CRSP stock has soared 64.5%.
Yahoo
an hour ago
- Yahoo
Why Flowers Foods (FLO) is a Top Food Stock for Dividend Investors
Flowers Foods, Inc. (NYSE:FLO) is included among the 10 Best Food Stocks with Dividends. A female baker in a spotless kitchen carefully decorating a cake. Flowers Foods, Inc. (NYSE:FLO) is an American company that manufactures a range of bakery products for both retail and foodservice markets nationwide. Its offerings include items like fresh bread, buns, rolls, snack cakes, and tortillas. The company supplies these products to grocery stores, convenience outlets, and restaurants. Among its most recognized brands are Nature's Own, Whitewheat, Cobblestone Bread, Wonder, Dave's Killer Bread, Canyon Bakehouse, Mrs. Freshley's, and Tastykake. Flowers Foods, Inc. (NYSE:FLO) has a strong cash position. In the most recent quarter, the company generated $135.6 million in operating cash flow, which grew by $30.5 million. The company also remained committed to its shareholder obligation, returning $52.3 million through dividends during the quarter, up $1.2 million from the previous quarter. Flowers Foods, Inc. (NYSE:FLO) currently offers a quarterly dividend of $0.2475 per share, having raised it by 3.1% in May. This was the company's 23rd consecutive year of dividend growth, which makes it one of the best food stocks with dividends. In addition, it has paid regular dividends to shareholders for 91 quarters in a row. The stock has a dividend yield of 6.09%, as of July 27. While we acknowledge the potential of FLO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: READ NEXT: and Disclosure: None.
Newsweek
5 hours ago
- Newsweek
Trump's 'Big, Beautiful Bill' 'A Gift' for Democrats, James Carville Says
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Veteran Democratic strategist James Carville on Monday said that the Donald Trump-backed "big, beautiful bill" is "a gift" for the Democratic Party. Why It Matters The One Big Beautiful Bill Act passed Congress earlier this month and aims to deliver on Trump's biggest legislative priorities: cementing the sweeping tax cuts, which disproportionately benefit wealthy Americans, enacted during his first term, and substantially increasing funds for border security and immigration enforcement. The Republican-passed bill pays for the tax cuts and increased border security with deep spending reductions in critical social safety net programs like Medicaid and food assistance. The nonpartisan Congressional Budget Office has estimated that the bill could result in 11.8 million more uninsured Americans by 2034 and add nearly $3.4 trillion to the federal deficit over the next decade. James Carville is pictured at Politicon in Pasadena, California, on June 25, 2016. James Carville is pictured at Politicon in Pasadena, California, on June 25, 2016. Colin Young-Wolff/Invision/AP What To Know Carville made his remarks during an appearance on Fox News, telling host Martha MacCallum that the massive spending package should be the Democratic Party's main messaging focus. "James, you've talked about, you know, them wasting time on some of these issues around trans sports and all this stuff," MacCallum said. "What substantive thing would you like to see them focus on? Because perhaps immigration is the one, and in what way?" "The 'big, beautiful bill,'" Carville responded. "Cutting veterans' benefits, closing rural hospitals, raising $3.4 trillion on our national debt. I mean, when you have something simple in a gift like this to contrast yourself, you would be stupid to talk about immigration, or talk about bathrooms, or track meets or anything else." He added: "Just define yourself that we don't think this is going in the right direction for the United States and the numbers overwhelmingly would support that! But if we keep talking about this other nonsense, we're going to lose our focus." House Minority Leader Hakeem Jeffries gave a marathon speech railing against the bill, which lasted eight hours and 44 minutes. "Republicans are trying to jam this one, big, ugly bill down the throats of the American people," Jeffries said during his "magic minute" speech. "Leadership requires courage, conviction, compassion—and yet what we have seen from this administration and co-conspirators on the Republican side of the aisle is cruelty, chaos and corruption," he said, adding that the bill was "an extraordinary assault on the health care of the American people." Other Democratic lawmakers also made headlines for their stinging rebukes of the megabill. "This bill will kill good, blue-collar manufacturing jobs that we need to rebuild the economy in this country," Democratic Representative Josh Riley of New York said during a floor debate. "It closes rural hospitals. It defunds health care. All to give trillions of dollars in tax cuts to your cronies." "Don't tell me you give a s*** about the middle class when all you are doing is s******* on the middle class," Riley added. Representative Alexandria Ocasio-Cortez, another Democrat from New York and one of the most progressive members of Congress, described the bill as a "deal with the devil" in an impassioned speech on the House floor. Democratic Massachusetts Representative Jim McGovern mocked Republicans for behaving like they were in a "cult" because of their support for the Trump-backed bill, despite recent polling data showing that it's broadly opposed by Americans. Several Republican senators have also faced scrutiny over comments they delivered regarding the cuts to Medicaid. Senator Joni Ernst of Iowa made headlines in May when she responded to people protesting Medicaid cuts by saying, "Well, we are all going to die." Kentucky Senator Mitch McConnell, former Senate majority leader, also told Republicans during a closed-door lunch in June: "I know a lot of us are hearing from people back home about Medicaid. But they'll get over it." What Happens Next Trump administration officials have continued touting the law since Trump signed it earlier this month as part of an effort to sell it to voters. "It is time for you to have a government that works for you instead of against you for the next 3 1/2 years," Vice President JD Vance told voters in his home state of Ohio on Monday. "The Trump administration promises that is exactly what we're going to do."
